Zhang Xiang Yang, Zhou Dong Feng, Cao Lian Yuan, Zhang Pei Yan, Wu Gui Ying, Shen Yu Cun
Institute of Mental Health, Peking University, Beijing, People's Republic of China.
Psychopharmacology (Berl). 2005 Feb;178(1):35-40. doi: 10.1007/s00213-004-1975-7. Epub 2004 Jul 31.
There are few data from systematic, double-blind clinical trials that have compared the effect of the typical and the atypical antipsychotics on serum prolactin (PRL) levels in patients with schizophrenia.
The goal of this study was to compare the effect of risperidone and haloperidol on serum PRL and investigate the relationship between serum PRL levels and clinical response in patients with schizophrenia.
Seventy-eight inpatients with a diagnosis of schizophrenia (according to DSM-III-R) were randomly assigned to 12 weeks of treatment with 6 mg/day of risperidone or 20 mg/day of haloperidol after a 2-week washout period, using a randomized, double-blind design. Clinical efficacy was determined using the positive and negative syndrome scale (PANSS). Their serum PRL was assayed by means of radioimmunometric assay (RIA) between pre-treatment and post-treatment, and compared with 30 sex-matched and age-matched normal subjects.
Both risperidone and haloperidol treatment significantly increased serum PRL levels in drug-free chronic schizophrenia patients (both P<0.001). Hyperprolactinemia induced by risperidone 6 mg/kg was comparable to levels produced by haloperidol 20 mg/day. Considering dose-adjusted serum PRL levels, risperidone treatment induced a significant elevation of PRL levels compared with haloperidol treatment at the haloperidol equivalent (P<0.001). Change in PRL levels at pre-treatment and post-treatment were related to positive symptom improvement seen in the risperidone group (r=0.51, P=0.016), but not in the haloperidol group (P>0.05). Female patients showed both a higher baseline and post-treatment PRL level and a greater increase in PRL than men (all P<0.05).
Risperidone is associated with a robust effect on prolactin secretion in contrast to the conventional antipsychotic haloperidol. Prolactin monitoring during risperidone treatment should be performed.
关于典型抗精神病药物和非典型抗精神病药物对精神分裂症患者血清催乳素(PRL)水平影响的系统双盲临床试验数据较少。
本研究旨在比较利培酮和氟哌啶醇对血清PRL的影响,并探讨精神分裂症患者血清PRL水平与临床反应之间的关系。
78例符合DSM-III-R诊断标准的精神分裂症住院患者,经过2周的洗脱期后,采用随机双盲设计,随机分配接受12周的治疗,其中一组为每天6mg利培酮,另一组为每天20mg氟哌啶醇。使用阳性和阴性症状量表(PANSS)确定临床疗效。在治疗前和治疗后通过放射免疫分析法(RIA)检测他们的血清PRL,并与30名性别和年龄匹配的正常受试者进行比较。
利培酮和氟哌啶醇治疗均显著提高了未使用药物的慢性精神分裂症患者的血清PRL水平(均P<0.001)。6mg/kg利培酮引起的高催乳素血症与20mg/天氟哌啶醇产生的水平相当。考虑到剂量调整后的血清PRL水平,与氟哌啶醇等效剂量相比,利培酮治疗导致PRL水平显著升高(P<0.001)。利培酮组治疗前和治疗后PRL水平的变化与阳性症状改善相关(r=0.51,P=0.016),而氟哌啶醇组则无此相关性(P>0.05)。女性患者的基线和治疗后PRL水平均高于男性,且PRL升高幅度更大(均P<0.05)。
与传统抗精神病药物氟哌啶醇相比,利培酮对催乳素分泌有显著影响。利培酮治疗期间应进行催乳素监测。